Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 2/20 | 0.43 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.42 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.42 |
| ▸ | CACNA1I | Q9P0X4 | 2/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.40 |
| ▸ | SCD | O00767 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.38 |
| ▸ | KLK1 | P06870 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6818812 | 0.91 | CHRM4 (0.37) | CHRM4CACNA1GCACNA1HCACNA1IPTGER4 | |
| SCHEMBL6818605 | 0.91 | ALDH1A1 (0.42) | CHRM4TRPA1SCDS1PR3 | |
| SCHEMBL6485426 | 0.86 | P2RY14 (0.36) | CHRM4CACNA1GCACNA1HCACNA1ISCD | |
| SCHEMBL6476858 | 0.82 | TRPA1 (0.49) | CHRM4CACNA1GCACNA1HCACNA1IPTGER4 | |
| SCHEMBL6478088 | 0.80 | PTGER4 (0.41) | CHRM4CACNA1GCACNA1HCACNA1IPTGER4 | |
| SCHEMBL6477648 | 0.80 | POLB (0.42) | CHRM4CACNA1GCACNA1HCACNA1IPTGER4 | |
| Picolamine SCHEMBL6818607 | 0.79 | PLA2G7 (0.34) | CACNA1GCACNA1HCACNA1ITRPA1S1PR3 | |
| Niacinamide SCHEMBL6818598 | 0.77 | FYN (0.39) | CACNA1GCACNA1HCACNA1IMAPT | |
| SCHEMBL6288790 | 0.76 | MAOB (0.48) | CHRM4CACNA1GCACNA1HCACNA1IPTGER4 | |
| SCHEMBL6288742 | 0.75 | MAPT (0.49) | TRPA1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004014908-A1 | HETEROBICYLCIC METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | claimed |
| US-6897223-B2 | Pyridine fused bicyclic metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-05-24 | — | — | US | disclosed |
| US-20040039012-A1 | Pyridine fused bicyclic metalloproteinase inhibitors | WILSON MICHAEL WILLIAM (US) | 2004-02-26 | — | — | US | disclosed |
| WO-2004014908-A1 | HETEROBICYLCIC METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039012-A1 | Pyridine fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | CHRM4 4702/4885CACNA1G 3912/4885CACNA1H 4095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.